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Abstract The diagnosis of Lyme neuroborreliosis (LNB) re-
quires the detection of intrathecal synthesis of Borrelia-specific
antibodies, but in very early disease, the sensitivity may be low.
We compared the performance of the second-generation IDEIA
Lyme Neuroborreliosis test (Oxoid), based on purified native
flagellum antigen, with two newly developed tests based on
several recombinant antigens for the diagnosis of LNB. Patients
investigated for LNB during 2003 through 2007 were included
(n =175); 52 with definite LNB, four with possible LNB and
119 non-LNB patients. Serum and cerebrospinal fluid (CSF)
were analysed with the IDEIA Lyme Neuroborreliosis (Oxoid),
VIDAS Lyme IgG (bioMérieux) and recomBead Borrelia IgM
and IgG (Mikrogen) assays. Intrathecal antibody indices (AIs)
were calculated according to the manufacturers’ protocols. The
IDEIA test performed with an overall sensitivity (IgM and IgG
AIs taken together) of 88 % and a specificity of 99 %. The
VIDAS test showed a sensitivity of 86 % and a specificity of
97 %. An overall sensitivity of 100 % and a specificity of 97 %
were achieved by the recomBead test. We conclude that the
three assays performed equally well regarding specificity, but
our data suggest an improved diagnostic sensitivity with the
recomBead Borrelia test.
Introduction
The tick-transmitted disease Lyme borreliosis is caused by
spirochetes belonging to the Borrelia burgdorferi sensu lato
(s.l.) genospecies complex. Three of the genospecies are most
frequently isolated from human specimens: B . afzelii , B .
garinii and B . burgdorferi sensu stricto (s.s.). Occasionally,
other genospecies have been associated with human disease,
e.g. B . spielmanii [1].
Lyme neuroborreliosis (LNB) is the most common mani-
festation of disseminated borreliosis in Europe [2–4]. The
symptoms and the disease course of LNB differ between
individuals, which is partly assumed to depend on which
genospecies causes the infection, e.g. B . garinii has been
associatedwithmore distinct symptoms andmore pronounced
intrathecal inflammation than B . afzelii [5].
The diagnosis of LNB is, according to current European
guidelines [6], based on the patient’s medical history, clinical
findings and analysis of cerebrospinal fluid (CSF) with con-
firmation by culture, polymerase chain reaction (PCR) or
specific anti-Borrelia antibody index (AI). The sensitivity of
culture and PCR in clinical specimens is, however, low
(10–30 %) [7–9], and, consequently, these methods are
of limited use. The detection of an elevated anti-
Borrelia AI remains the main confirmatory tool in
LNB diagnostics. Rapid and easy-to-use tests delivering
clear-cut results are important for laboratories analysing
large numbers of samples. A rapid and reliable diagno-
sis of LNB is essential for patients, since delayed anti-
biotic treatment is associated with slower recovery and
persistent symptoms [10, 11].
First-generation anti-Borrelia antibody tests were based on
whole-cell sonicates and had poor specificity due to cross-
reactive antibodies [9, 12, 13]. The second generation of
antibody tests, based on purified nativeBorrelia antigens such
as the flagellum protein, have improved the specificity [13].
Now, third-generation antibody tests based on synthetic pep-
tides and recombinant antigens are available [12], and the use
of these tests might further improve both the sensitivity and
specificity in LNB diagnostics.
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The aim of this study was to compare the diagnostic
performance of the second-generation IDEIA Lyme
Neuroborreliosis test (Oxoid, Hampshire, UK), currently in
use in our laboratory, but with a limited sensitivity in very
early LNB [14], with two third-generation antibody assays
based on several recombinant antigens for the laboratory
diagnosis of LNB. Since comparisons of antibody assays are
often complicated by the lack of gold standards, much effort
was directed to the definition and characterisation of the
included patients.
Materials and methods
Study populations and clinical specimens
Serum and CSF specimens were selected retrospectively from
175 clinically well-characterised individuals who had been
investigated for suspected LNB from 2003 through 2007 in
Jönköping County, Sweden (Table 1). Fifty-two patients had
definite LNB according to the European guidelines [6]; neu-
rological symptoms consistent with LNB (one or several of
the following symptoms: headache/neck pain n =35; cranial
nerve palsy n =33; muscle/joint pain n =27; radiculitis n =22;
paresthesia n =22; vertigo n =6), CSF pleocytosis (mononu-
clear cell count >5/μL) and elevated anti-Borrelia AI. The
Lyme Borreliosis ELISA kit 2nd Generation (Dako
Cytomation A/S, Glostrup, Denmark), which is based on
purified native flagellum from B . burgdorferi , was used as
the routine method for both serum and CSF at the Department
of Clinical Microbiology, Ryhov County Hospital, Jönköping,
Sweden, during the sampling period. TheBorrelia-specific AI
was calculated as described by Peter [15], with the modifica-
tion that total IgG was substituted for Rubella -specific IgG.
The formula used was: [Borrelia-specific IgG in CSF (OD)/
Borrelia-specific IgG in serum (OD)]/[Rubella -specific IgG
in CSF (OD)/Rubella -specific IgG in serum (OD)]. From
September 2004, the laboratory used total IgG as the reference
molecule. Eight of the patients in the definite LNB group had
Borrelia -specific IgM alone in serum with the Lyme
Borreliosis ELISA kit 2nd Generation, 11 patients had only
IgG in serum, 26 had IgM and IgG, and seven had no
Borrelia-specific antibodies detectable in serum. The LNB
patients were clinically evaluated regarding symptoms, course
of the disease and response to therapy by review of their
medical records according to a standardised protocol. Further-
more, they had been part of previous studies [11, 16, 17], and
were characterised regarding cytokine and chemokine patterns
in serum and in CSF. All of the LNB patients, except four
(48/52), displayed high CSF levels (>500 pg/mL) of the B
cell attractant chemokine CXCL13, which has recently
been shown to be a reliable marker of active LNB [18, 19].
The four LNB patients with lower CXCL13 levels in CSF
(<7.8–363 pg/mL) presented with neurological symptoms (at
least two of the following: headache/neck pain n =2; muscle/
joint pain n =3; radiculitis n =2; paresthesia n =1; vertigo n =1;
cognitive dysfunction n =1) and responded well to antibiotic
treatment. Twenty-two of the 52 patients with definite LNB
were children under 18 years of age, comprising 15 boys and
seven girls.
In addition, four patients with possible LNBwere included;
one adult with radiculitis and more than a two-fold increase of
anti-Borrelia antibody levels in serum at follow-up, one child
with facial palsy who had an erythema migrans 3 weeks
earlier, one adult with meningitis and facial palsy, and one child
with facial palsy. They all had CSF pleocytosis and a recent
onset of their symptoms at presentation (2 days–3 weeks), but
an elevated anti-Borrelia AI was not detected by the Lyme
Borreliosis ELISA kit 2nd Generation. Three of the patients
had both Borrelia -specific IgM and IgG in serum, and one
patient had only IgG. Three of the patients had high
levels of CXCL13 in their CSF (>500 pg/mL). All of
them received antibiotic treatment (ceftriaxone or doxycycline)
and responded promptly to therapy.
Serum and CSF samples from 119 non-LNB patients were
included as a reference group. Twenty-nine of these patients
had CSF pleocytosis, but no elevated anti-Borrelia AI was
detected by the Lyme Borreliosis ELISA kit 2nd Generation.














LNB patients Definite LNBb, n=52 + + +/− 21; 1–224 64 39; 3–85
Possible LNB, n =4 + − + 9; 2–21 75 30; 4–49
Non-LNB patients Pleocytosis for other
reason, n =29
+ − +/− 7; 1–1,092 41 38; 17–80
No pleocytosis, n =90 − − − n.d.c 38 45; 11–89
aCSF cerebrospinal fluid
b LNB Lyme neuroborreliosis
c n.d. not determined
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Six of these patients had positive or equivocal results for IgM
in serum with this test, one patient had Borrelia -specific IgG
and the remaining 22 patients had no detectable anti-Borrelia
antibodies in serum. Within this group, ten patients were
diagnosed with viral meningitis, seven with multiple sclerosis,
three with cerebral tumour, one withMycoplasma pneumoniae
encephalitis, one with endocarditis lenta, one with drug intox-
ication, one with Bell’s palsy, one with migraine and sciatica,
three with suspected autoimmune diseases and one with sub-
arachnoid haemorrhage. The remaining 90 patients had a nor-
mal CSF cell count, a normal CSF:serum albumin ratio and no
detectable anti-Borrelia antibodies in CSF or serum using the
Lyme Borreliosis ELISA kit 2nd Generation.
Furthermore, serum samples from 90 healthy blood donors
(male:female ratio=47:42, age=30–61 years, median
46 years) were analysed with the VIDAS Lyme IgG and
IgM assay and the recomBead Borrelia IgG and IgM assay,
and used for comparison with the serum results in our non-
LNB group.
Serum and CSF samples had been stored at −20 °C.
Methods
Serum and CSF specimens were tested in parallel with three
antibody assays. IDEIA Lyme Neuroborreliosis is an enzyme
immunoassay (EIA) based on purified native flagellum from
B . afzelii strain DK1. This test determines intrathecally pro-
duced anti-Borrelia IgM and IgG, with no need for correction
of passive transudation of serum antibodies. VIDAS Lyme
IgG (bioMérieux, Marcy l’Etoile, France) is a random access
enzyme-linked fluorescent assay (ELFA) based on the recom-
binant Borrelia proteins variable major protein-like sequence-
expressed (VlsE), decorin-binding protein A (DbpA) and
outer surface protein C (OspC). Only anti-Borrelia IgG is
measured in CSF specimens with this test, and the AI is
calculated for all antigens together in relation to either the
CSF:serum albumin ratio or the CSF:serum total IgG ratio
[20, 21]. The recomBead Borrelia IgM and IgG assay
(Mikrogen GmbH, Neuried, Germany) is a multiplex bead
array using Luminex xMAP technology and, in this study, a
Bio-Plex 200 System (Bio-Rad Laboratories, Inc., Hercules,
CA, USA) was used together with the software Xponent,
version 3.1.871.0 (Luminex Corporation, Austin, TX, USA).
The test includes several recombinant Borrelia antigens at-
tached to polystyrene beads: p100 fromB . afzelii , VlsE fusion
protein representing different genospecies, p58 from B .
garinii , p39 from B . afzelii , OspA from B . afzelii , OspC
from B . burgdorferi s.s., B .afzelii and B . garinii , p18/
DbpA from B . burgdorferi s.s., B . afzelii , B . garinii , B .
bavariensis and B . spielmanii . Intrathecal AI is calculated
for each antigen separately according to Reiber and Peter [22]
by the Excel program available fromMikrogen, and an overall
assessment of the test result is given. Cut-off levels and
interpretation criteria were applied as recommended by the
manufacturer for each test, and equivocal results were
regarded as positive.
Albumin, total IgM and total IgG were measured in serum
and in CSF by rate nephelometry with the Immage 800
instrument (Beckman Coulter, Fullerton, CA, USA).
Statistics
Statistical analysis was performed using SPSS version 15.0
(SPSS Inc., Chicago, IL, USA). For pairwise comparison of
the antibody assays, McNemar’s test with Yate’s correction
was applied, and two-tailed p -values <0.05 were considered
to be significant.
Ethics
The study was approved by the Regional Ethical ReviewBoard
in Linköping, Sweden (M83-05 T91-08, 2012/246-31). Per-
mission to read the patients’ medical records was given by the
medical director of each clinic.
Results
Intrathecal antibody indices
The test results based on intrathecal anti-Borrelia IgM and
IgG AIs are presented in Table 2. Overall sensitivities and
specificities (IgM and IgG AIs taken together) were calculated
for LNB patients (n =56) and non-LNB patients (n =119)
(Table 2). Pairwise comparison of the overall test perfor-
mances for all patients (n =175) did not reveal any significant
differences between the three assays.When comparing the test
performances in only the LNB group (n =56), the recomBead
assay had significantly more positive results than the IDEIA
Lyme Neuroborreliosis assay (p =0.016) and the VIDAS
Lyme IgG assay (p =0.008). There was no significant differ-
ence between the IDEIA and VIDAS assays (p =1.0).
In the IDEIA Lyme Neuroborreliosis test, nine (17 %) of
the 52 patients with definite LNB had elevated anti-Borrelia
IgM AI alone, 11 (21 %) had only elevated anti-Borrelia IgG
AI and 28 (54 %) patients had elevated AI for both anti-
Borrelia IgM and IgG. In the recomBead Borrelia test, nine
(17 %) of the patients with definite LNB had elevated anti-
Borrelia IgG AI alone, 43 (83 %) had elevated AI for both
anti-Borrelia IgM and IgG, but none of the patients had an
elevated AI for anti-Borrelia IgM alone. In the possible LNB
group, one of the four patients had an elevated IgM AI alone
with the IDEIA test. This patient had an elevated IgG AI
according to the VIDAS Lyme IgG assay, and elevated IgM
and IgG AIs according to the recomBead Borrelia test. Two of
the four patients with possible LNB had elevated IgM and IgG
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AIs with the recomBead test, and two patients had elevated
IgG AIs alone.
No equivocal interval for the test results are given by the
manufacturer of the IDEIA Lyme Neuroborreliosis test,
whereas equivocal intervals are defined for both the VIDAS
Lyme IgG and the recomBead Borrelia IgM and IgG assays.
No equivocal AIs were obtained with the VIDAS Lyme IgG
test, but one patient with definite LNB had an equivocal IgG
AI in the recomBead test.
In the VIDAS Lyme IgG assay, the intrathecal AI was
calculated based on both the CSF:serum albumin ratio and
the CSF:serum total IgG ratio. When the albumin ratio was
used, 43 of the 52 definite LNB cases had an elevated anti-
Borrelia AI, and when using the total IgG ratio, an additional
two patients had an elevated AI (in total, 45/52).
The number of definite and possible LNB patients with
positive AI in each test in relation to the duration of neuro-
logical symptoms is presented in Fig. 1a. Data on the duration
of symptoms was lacking in three of the 56 cases.
Serum
The serum results for the VIDAS Lyme IgM and IgG and for
the recomBead Borrelia IgM and IgG tests are presented in
Table 3. For the VIDAS Lyme IgM and IgG assay, two
patients with definite LNB had equivocal IgM results in serum
and three patients in the non-LNB group had equivocal serum
IgM results. As for the recomBead Borrelia IgM and IgG
assay, one equivocal test result was obtained from the serum
analyses; one patient with definite LNB had an equivocal
value for serum IgM. The number of definite and possible
LNB patients with anti-Borrelia IgM and/or IgG detectable in
serum with each test in relation to the duration of neurological
symptoms is presented in Fig. 1b.
In the recomBead Borrelia IgM and IgG test, the antibody
reactivities seen in serum from the LNB patients (n =56) were
directed against VlsE in 100 % of the cases, OspC in 79 %,
p18/DbpA in 52 %, p58 in 50 %, p39 in 46 %, p100 in 43 %
and OspA in 9 %. All OspC-reactive samples showed reac-
tivity against OspC from at least two of the included Borrelia
species (B . burgdorferi s.s., B .afzelii and B . garinii ). Sera
reactive against p18/DbpA, on the other hand, generally
showed reactivity against p18/DbpA from only one of the
represented Borrelia species (B . burgdorferi s.s., B . afzelii ,
B . garinii , B . bavariensis and B . spielmanii), most frequently
against B . garinii (79 %).
In addition, serum samples from 90 healthy blood donors
were analysed with the VIDAS Lyme IgM and IgG assay and
with the recomBead Borrelia IgM and IgG assay, and a
seropositivity of 11 % was found with both tests. Eight of
the blood donors who had positive test results with the VIDAS
Lyme IgG and IgM assay also tested positive with the
recomBead Borrelia IgM and IgG assay. The IgM and/or
IgG seropositivity in the non-LNB group (n =119) was 14 %
in the VIDAS Lyme IgM and IgG test and 15 % in the
recomBead Borrelia IgM and IgG test.
Discussion
In this study, we compared the diagnostic performance of the
second-generation IDEIA Lyme Neuroborreliosis test with
Table 2 Overall test results for intrathecal anti-Borrelia antibody indices (AIs)
IDEIA Lyme Neuroborreliosis
LNBa patients Non-LNB patients Sensitivity: 88 %b
Specificity: 99 %Definite LNB, n =52 Possible LNB, n =4 Pleocytosis for other
reason, n =29
No pleocytosis, n=90
Positive IgM and/or IgG index 48 1 1 0
Negative IgM and IgG index 4 3 28 90
VIDAS Lyme IgG
LNB patients Non-LNB patients Sensitivity: 86 %
Specificity: 97 %Definite LNB, n =52 Possible LNB, n =4 Pleocytosis for other
reason, n =29
No pleocytosis, n=90
Positive IgG index 45 3 2 1
Negative IgG index 7 1 27 89
recomBead Borrelia IgM and IgG
LNB patients Non-LNB patients Sensitivity: 100 %
Specificity: 97 %Definite LNB, n =52 Possible LNB, n =4 Pleocytosis for other
reason, n =29
No pleocytosis, n=90
Positive IgM and/or IgG index 52 4 3 1
Negative IgM and IgG index 0 0 26 89
a LNB Lyme neuroborreliosis
b Sensitivity and specificity calculations are based on the LNB group (n =56) and the non-LNB group (n =119)
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two third-generation assays in serum and CSF from 175
clinically well-defined patients for the diagnosis of LNB. We
found that, when serum and CSFwere tested in parallel andAIs
were calculated according to the manufacturers’ instructions,
all three assays performed equally well regarding the specificity
(97–99 %). However, the IDEIA Lyme Neuroborreliosis assay
is based on the same antigen as the Lyme Borreliosis ELISA kit
2nd Generation that was used for the selection of the patient
groups, and, thus, the specificity of the IDEIA test cannot be
reliably evaluated. The IDEIA Lyme Neuroborreliosis test and
the VIDAS Lyme IgG test had a sensitivity of 88 % and 86 %,
respectively, whereas a sensitivity of 100 % was achieved by
the recomBead Borrelia IgM and IgG test, and the difference
between the recomBead test and the other two assays was
statistically significant in the LNB group. When comparing
the test performances for all the included patients (LNB and
non-LNB), however, the differences between the tests did not
reach statistical significance.
All three assays gave elevated AIs in some of the non-LNB
patients, especially in the group of patients with CSF
pleocytosis for other reason (Table 2). This could be due to
unspecific antibody reactivities, but it is also possible that
these elevated AIs are correct, since the classification of
patients was based on the older Lyme Borreliosis ELISA kit
2nd Generation, and that the patients, according to their
medical records, were diagnosed with conditions other than
LNB. However, the negative test result of the anti-Borrelia
antibody analysis may have influenced the clinical diagnosis.
Therefore, it is possible that some of the patients classified in
the non-LNB group actually had LNB. Contradicting this
hypothesis, none of the six patients had positive AI in more
than one of the evaluated assays.
Almost no equivocal AIs were obtained using the assays
tested, which is considered advantageous for the interpretation
of test results in the clinical laboratory setting. The use of the
CSF:serum total IgG ratio in the calculation of AIs seems to be
Duration of symptoms (days)
























































































Fig. 1 Number of definite and possible Lyme neuroborreliosis (LNB)
patients with positive anti-Borrelia IgM and/or IgG antibody index (a)
and anti-Borrelia IgM and/or IgG in serum (b) in each test in relation to
the duration of neurological symptoms. Data on symptom duration were
missing in three cases. The total number of patients (n) in each time
interval is indicated
Table 3 Overall test results for anti-Borrelia serum antibodies
VIDAS Lyme IgM and IgG
LNBa patients Non-LNB patients Sensitivity: 93 %c
Specificity: 86 %Definite LNB, n =52 Possible LNB, n =4 Pleocytosis for other
reason, n =29
No pleocytosis, n =90
Positive Sb-IgM and/or S-IgG 48 4 8 9
Negative S-IgM and S-IgG 4 0 21 81
recomBead Borrelia IgM and IgG
LNB patients Non-LNB patients Sensitivity: 86 %
Specificity: 85 %Definite LNB, n =52 Possible LNB, n =4 Pleocytosis for other
reason, n =29
No pleocytosis, n =90
Positive S-IgM and/or S-IgG 45 3 7 11
Negative S-IgM and S-IgG 7 1 22 79
a LNB Lyme neuroborreliosis
b S serum
c Sensitivity and specificity calculations are based on the LNB group (n =56) and the non-LNB group (n =119)
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better than the albumin ratio when using the VIDAS Lyme IgG
assay.
All of the 56 patients with definite and possible LNB were
identified as having positive anti-Borrelia AI in the
recomBead Borrelia IgM and IgG test, whereas the other
two tests gave negative test results in seven and eight of the
cases, respectively. Most of the patients with negative AIs in
the IDEIA Lyme Neuroborreliosis test and the VIDAS Lyme
IgG test had short duration of their neurological symptoms
(<2 weeks), but the VIDAS assay gave negative results for
two patients who presented with symptoms lasting for more
than a month.
In this study, we have considered IgM AI and IgG AI as
equivalent. It is our opinion that the finding of an elevated
IgM AI is almost as reliable as an elevated IgG AI in LNB,
especially when the medical history, clinical findings and
other laboratory findings are in accordance with the diagnosis.
If a patient presents with an elevated IgM AI, IgG AI or both,
it probably depends on the duration of neurological symp-
toms, biological variations in the immune response and what
antigen is used in the assay.
The analysis of anti-Borrelia antibodies in serum samples
alone showed lower specificity in both the VIDAS Lyme IgM
and IgG and the recomBead Borrelia IgM and IgG tests.
Furthermore, by using the latter test, serum analysis alone also
showed a lower sensitivity than the AI. These results empha-
sise the importance of simultaneous analysis of serum and
CSF samples for the diagnosis of LNB. In addition, we found
more equivocal test results in serum than in AIs, especially
with the VIDAS Lyme IgM and IgG assay.
The observation that serum samples with antibody reactiv-
ities against OspC in the recomBead Borrelia IgM and IgG
test consequently displayed reactivity against OspC from at
least two Borrelia species indicates that the response to OspC
antigens overlap. However, this seems not to be the case for
p18/DbpA, where antibody reactivity, generally, was directed
against p18/DbpA from only one species per patient. Whether
this indicates the causative Borrelia species in individual
LNB cases remains to be investigated, perhaps by confirma-
tion with PCR and DNA sequencing. However, this may be
challenging, since these methods have low sensitivity in CSF
and serum specimens.
The seropositivity rate found in the 90 blood donors cor-
roborates previous observations of Borrelia seroprevalence in
southern Sweden [23], and was in the same range as the non-
LNB patients, thus, affirming both the specificity of the test
results and the use of the non-LNB group as a reference group.
All three assays, especially the VIDAS Lyme IgM and IgG
test, were easy to perform. The VIDAS instrument allows
random access and, thereby, facilitates rapid test results. The
calculation of AIs with both the VIDAS Lyme IgG and the
recomBead Borrelia IgM and IgG tests requires the analysis of
albumin and total IgG (even total IgM for the latter test) in serum
and in CSF, which is a disadvantage compared to the IDEIA
Lyme Neuroborreliosis assay in terms of cost and ease of use.
The recomBead Borrelia IgM and IgG assay is the most expen-
sive of the three tests, and requires access to rather advanced
technology (Luminex xMAP). The VIDAS Lyme IgM and IgG
test also requires the use of a special instrument (VIDAS from
bioMérieux, Marcy l’Etoile, France), whereas the IDEIA Lyme
Neuroborreliosis test does not. The Borrelia-specific AI is cal-
culated manually from the VIDAS Lyme IgG results in serum
and in CSF and from total IgG or albumin in serum and in CSF.
Another disadvantage with the test may be the lack of anti-
Borrelia IgM analysis in CSF specimens, which possibly de-
creases the sensitivity of the test in very early LNB [24].
In conclusion, the analysis of anti-Borrelia antibodies si-
multaneously in serum and in CSF is essential for the accurate
diagnosis of LNB. The three assays compared in this study
performed equally well regarding their specificity, but the data
suggest an improved diagnostic sensitivity with the
recomBead Borrelia test.
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